Developer docs
API playgroundTry for free, no card

Search company profiles

MPM Capital

Full company profile

uuid0000agx

Namestring
MPM Capital
Legal namestring
MPM BioImpact LLC
Websiteurl
mpmcapital.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

MPM Capital, operating under the brand MPM BioImpact LLC, is a Boston-headquartered biotechnology investment firm founded in 1996 that invests across private and public companies throughout the drug development lifecycle. The firm combines capital deployment with hands-on company creation, building businesses from scientific breakthroughs (for example, Orna Therapeutics from MIT circular RNA research and Aktis Oncology from an in-house radiopharmaceutical concept) and supporting them through clinical and regulatory milestones toward exits.

The investment portfolio spans oncology, immunology, neuroscience, and genetic medicine, with notable positions including argenx (developer of the first approved FcRn blocker VYVGART), Orna Therapeutics (circular RNA medicines acquired by Eli Lilly for approximately $2.4 billion), Aktis Oncology (alpha radiopharmaceuticals, IPO'd in 2025), Reunion Neuroscience (psychedelic-inspired 5-HT2AR agonist RE104, FDA Breakthrough Therapy Designation 2026), and Firefly Bio (degrader-antibody conjugates, acquired by Johnson & Johnson). The firm cites 30+ years of biotech investing experience, 60 FDA-approved drugs associated with portfolio companies, and 120+ M&A and IPO events as core track-record metrics.

MPM BioImpact generates revenue through management fees on investment funds and carried interest from portfolio exits rather than product sales. The firm is privately held with 11-50 employees and operates with no disclosed AI/ML or software-product capabilities, distributing capital and strategic support rather than products or services to end customers.

Short descriptiontext

MPM Capital (MPM BioImpact) is a Boston-based biotech investment firm founded in 1996 that builds and funds private and public therapeutic companies across oncology, immunology, neuroscience, and genetic medicine, generating returns through portfolio exits and fund management fees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture capital, life sciences investing, biotechnology investment funds, therapeutics venture capital, private equity biotech
Industry1 code
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital / Life Sciences Investing
Social media profiles2 records
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MPM Capital (also operating as MPM BioImpact) is a biotechnology investment firm that manages venture capital and private equity funds providing capital and strategic support to private and public biotech companies across all stages of drug development—from discovery through regulatory approval and commercialization. The firm focuses on oncology, immunology, neurology, and genetic medicine, and is known for both funding and actively building companies around transformative therapeutic platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 60 FDA-approved drugs
+2 more records
Product overview1 text field

MPM BioImpact is a biotech investment and venture capital firm that builds and funds companies across the drug development process. Rather than offering a unified software platform or product suite, the firm operates investment funds that provide capital and strategic support to portfolio companies developing therapeutics. The portfolio includes Orna Therapeutics (circular RNA medicines), Aktis Oncology (alpha radiopharmaceuticals), Reunion Neuroscience (psychedelic-inspired mental health treatments), argenx (FcRn blocker VYVGART), and numerous other biotech companies across oncology, immunology, neurology, and genetic medicine.

Product and service1 record
1MPM BioImpact Investment Funds
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Orna Therapeutics, a portfolio company founded and built by MPM BioImpact, established a strategic collaboration with Vertex Pharmaceuticals to develop next generation approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). This collaboration leverages Orna's circular RNA technology platform combined with Vertex's expertise in genetic diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based early-stage biotech venture firm that builds and funds therapeutic companies from inception — directly comparable to MPM's company-creation model in life sciences.

TypeDirect peer
Description

Cambridge-based biotech innovation engine that originates and grows breakthrough therapeutic platforms — comparable to MPM in modality-driven company creation.

TypeDirect peer
Description

Boston-based biotech VC focused on building and launching therapeutic companies — closely aligned with MPM's entrepreneur-led, company-creation approach.

TypeDirect peer
Description

Long-tenured biotech-focused VC investing across private and public companies across drug development — comparable mandate and stage breadth to MPM.

TypeDirect peer
Description

Healthcare-dedicated investment firm covering therapeutics, devices, and diagnostics across stages — directly comparable to MPM's healthcare-only focus.

6Baker Bros. Advisors
TypeDirect peer
Description

Biotech-focused investment adviser investing across public and private therapeutics — directly comparable to MPM as a long-duration biotech specialist.

TypeDirect peer
Description

Early-stage life-sciences VC building companies around breakthrough science — comparable company-creation orientation and stage profile to MPM.

TypeDirect peer
Description

Healthcare-focused VC with dedicated biotech and medtech franchises — comparable stage breadth and therapeutic focus to MPM.

TypeDirect peer
Description

Healthcare-focused crossover and public-private investor — comparable mandate of investing across private and public biotech companies.

TypeBroad incumbent
Description

Large generalist VC with a dedicated Bio/Health fund targeting therapeutics platforms — overlapping with MPM's biotech investment activity but operating at much greater scale and across broader sectors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment303 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MPM Capital

Venture Capital / Life Sciences Investingmpmcapital.com

MPM Capital (MPM BioImpact) is a Boston-based biotech investment firm founded in 1996 that builds and funds private and public therapeutic companies across oncology, immunology, neuroscience, and genetic medicine, generating returns through portfolio exits and fund management fees.

What MPM Capital does

MPM Capital, operating under the brand MPM BioImpact LLC, is a Boston-headquartered biotechnology investment firm founded in 1996 that invests across private and public companies throughout the drug development lifecycle. The firm combines capital deployment with hands-on company creation, building businesses from scientific breakthroughs (for example, Orna Therapeutics from MIT circular RNA research and Aktis Oncology from an in-house radiopharmaceutical concept) and supporting them through clinical and regulatory milestones toward exits.

The investment portfolio spans oncology, immunology, neuroscience, and genetic medicine, with notable positions including argenx (developer of the first approved FcRn blocker VYVGART), Orna Therapeutics (circular RNA medicines acquired by Eli Lilly for approximately $2.4 billion), Aktis Oncology (alpha radiopharmaceuticals, IPO'd in 2025), Reunion Neuroscience (psychedelic-inspired 5-HT2AR agonist RE104, FDA Breakthrough Therapy Designation 2026), and Firefly Bio (degrader-antibody conjugates, acquired by Johnson & Johnson). The firm cites 30+ years of biotech investing experience, 60 FDA-approved drugs associated with portfolio companies, and 120+ M&A and IPO events as core track-record metrics.

MPM BioImpact generates revenue through management fees on investment funds and carried interest from portfolio exits rather than product sales. The firm is privately held with 11-50 employees and operates with no disclosed AI/ML or software-product capabilities, distributing capital and strategic support rather than products or services to end customers.

MPM Capital firmographics

Firmographics
Name
MPM Capital
Legal name
MPM BioImpact LLC
Website
https://mpmcapital.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
MPM Capital (MPM BioImpact) is a Boston-based biotech investment firm founded in 1996 that builds and funds private and public therapeutic companies across oncology, immunology, neuroscience, and genetic medicine, generating returns through portfolio exits and fund management fees.
Ownership category
akta.pro rank

MPM Capital industry classification

Industry
Product category
Venture Capital / Life Sciences Investing
NAICS
Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing

Keywords

  • Biotech venture capital
  • Life sciences investing
  • Biotechnology investment funds
  • Therapeutics venture capital
  • Private equity biotech

Where MPM Capital is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MPM Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Marketing channels3 records

MPM Capital product offering

Product offering

Core offering

MPM Capital (also operating as MPM BioImpact) is a biotechnology investment firm that manages venture capital and private equity funds providing capital and strategic support to private and public biotech companies across all stages of drug development—from discovery through regulatory approval and commercialization. The firm focuses on oncology, immunology, neurology, and genetic medicine, and is known for both funding and actively building companies around transformative therapeutic platforms.

Product overview

MPM BioImpact is a biotech investment and venture capital firm that builds and funds companies across the drug development process. Rather than offering a unified software platform or product suite, the firm operates investment funds that provide capital and strategic support to portfolio companies developing therapeutics. The portfolio includes Orna Therapeutics (circular RNA medicines), Aktis Oncology (alpha radiopharmaceuticals), Reunion Neuroscience (psychedelic-inspired mental health treatments), argenx (FcRn blocker VYVGART), and numerous other biotech companies across oncology, immunology, neurology, and genetic medicine.

Differentiator

Problem solved

Functional benefit

Products and services

  • MPM BioImpact Investment Funds

Quantifiable outcome

  • 60 FDA-approved drugs
  • +2 more outcomes

Companies that use MPM Capital

Customer profile

Segments1 record

Ideal customer profiles1 record

MPM Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MPM Capital partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Vertex PharmaceuticalscoreStrategic or Co-development Partner · 7 January 2025Orna Therapeutics, a portfolio company founded and built by MPM BioImpact, established a strategic collaboration with Vertex Pharmaceuticals to develop next generation approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). This collaboration leverages Orna's circular RNA technology platform combined with Vertex's expertise in genetic diseases.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

MPM Capital competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Boston-based early-stage biotech venture firm that builds and funds therapeutic companies from inception — directly comparable to MPM's company-creation model in life sciences.
  • Flagship Pioneering: Cambridge-based biotech innovation engine that originates and grows breakthrough therapeutic platforms — comparable to MPM in modality-driven company creation.
  • Third Rock Ventures: Boston-based biotech VC focused on building and launching therapeutic companies — closely aligned with MPM's entrepreneur-led, company-creation approach.
  • ARCH Venture Partners: Long-tenured biotech-focused VC investing across private and public companies across drug development — comparable mandate and stage breadth to MPM.
  • OrbiMed Advisors: Healthcare-dedicated investment firm covering therapeutics, devices, and diagnostics across stages — directly comparable to MPM's healthcare-only focus.
  • Baker Bros. Advisors: Biotech-focused investment adviser investing across public and private therapeutics — directly comparable to MPM as a long-duration biotech specialist.
  • 5AM Ventures: Early-stage life-sciences VC building companies around breakthrough science — comparable company-creation orientation and stage profile to MPM.
  • Versant Ventures: Healthcare-focused VC with dedicated biotech and medtech franchises — comparable stage breadth and therapeutic focus to MPM.
  • RA Capital Management: Healthcare-focused crossover and public-private investor — comparable mandate of investing across private and public biotech companies.

Broad incumbents

  • Andreessen Horowitz (a16z Bio): Large generalist VC with a dedicated Bio/Health fund targeting therapeutics platforms — overlapping with MPM's biotech investment activity but operating at much greater scale and across broader sectors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

MPM Capital social profiles

Digital presence

MPM Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MPM Capital leadership team

Management profile

Number of profiles

Profiles9 records

MPM Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MPM Capital M&A and investment

M&A and investment

M&A2 records

Investments303 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MPM Capital

What does MPM Capital do?

MPM Capital (also operating as MPM BioImpact) is a biotechnology investment firm that manages venture capital and private equity funds providing capital and strategic support to private and public biotech companies across all stages of drug development—from discovery through regulatory approval and commercialization. The firm focuses on oncology, immunology, neurology, and genetic medicine, and is known for both funding and actively building companies around transformative therapeutic platforms.

When was MPM Capital founded?

MPM Capital was founded in 1996. It employs 11 to 50 people.

Where is MPM Capital based?

MPM Capital is headquartered in Boston, United States, in the North America region.

Who are MPM Capital's main competitors?

Direct peers on record are Atlas Venture, Flagship Pioneering, Third Rock Ventures, ARCH Venture Partners, OrbiMed Advisors, Baker Bros. Advisors, 5AM Ventures, Versant Ventures and RA Capital Management. Andreessen Horowitz (a16z Bio) is listed as a broad incumbent.

Does MPM Capital have an API?

No public API is recorded for MPM Capital.

What industry is MPM Capital in?

MPM Capital's product category is Venture Capital / Life Sciences Investing. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comMpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.comMPM BioVentures 2018, L.P., a 10% owner and director of Entrada Therapeutics, sold 62,714 shares totaling $461,545 over three days from August 24 to 26, 2026, at prices between $7.06 and $7.54 per share. The fund now holds 4,318,348 shares, and Entrada trades near $7 with a $252 million market cap. Entrada's Data Monitoring Committee approved a 10 mg/kg dose in its DMD ELEVATE-45-201 study.Investing.comMpm Bioventures 2018 sells $461,545 of Entrada Therapeutics stock By Investing.comMPM BioVentures 2018, L.P., a 10% owner and director of Entrada Therapeutics, sold 62,714 shares totaling $461,545 over three days from August 24 to 26, 2026, at prices between $7.06 and $7.54 per share. The fund now holds 4,318,348 shares, with the stock down roughly 8% and a market cap of $252 million. Entrada's DMD ELEVATE-45-201 study received approval to advance Cohort 2 at 10 mg/kg.BioSpaceIn Tough Market, CODA Quietly Shuts DoorsCODA Biotherapeutics, a Bay Area biotech company, has ceased operations and is listed as permanently closed, with investors Versant Ventures and MPM Capital confirming the shutdown. The closure occurs amidst a broader downturn in the life science sector characterized by slim funding and increased layoffs across the industry. While specific reasons for CODA's failure were not disclosed, the event highlights the challenging financial environment forcing companies to make tough calls to survive.PRLogM3M Capital Walk - An Upcoming Commercial Property At Sector 113, GurgaonM3M Capital Walk in Sector 113, Gurgaon, is an upcoming commercial property with retail, office, and serviced apartments. It includes a club, bar, restaurant, swimming pool, and gym, with safety systems like fire sprinklers and CCTV. The project is positioned as a high-street retail hub with diverse offerings.BioSpacePhotys Leads Spate of Series A Announcements with $75M for PHICSPhotys Therapeutics launched with $75 million in financing to develop phosphorylation-inducing chimeric small molecule medicines targeting underserved diseases. The funding round was led by MPM Capital and supported by investors including Merck and Eli Lilly. Photys aims to treat cancer and other critical diseases using its innovative approach to modulate protein functions through precise phosphorylation.PRLogFantastic Spread of Beauty Homes in M3M CapitalM3M Capital launched a new luxury residential project in Sector-113 Gurgaon, featuring a clubhouse with a swimming pool, spa, gym, and other amenities. The project emphasizes green landscaping and proximity to schools, healthcare, malls, and public transport.PRLogEnjoy the supreme luxuries in M3M Capital GurgaonM3M Capital Gurgaon, a new residential township in Sector 113, offers 2 and 3 BHK flats from 1600 to 2600 sqft. The project features amenities like a pool, gym, and playground, and is adjacent to a metro station with easy access to Delhi airport and NCR.PRLogM3M Luxury Apartments - M3M Capital, Sector 113, GurgaonM3M Luxury Apartments in Sector 113, Gurgaon, is a modern residential complex built on a large acreage by ARCOP International. The apartments feature spacious layouts, huge balconies, and windows with natural ventilation, and are marketed as a luxury residence for both living and investment.PRLogM3M Capital Sector 113 Gurgaon | The Apartment Of Your DreamsM3M Capital Sector 113 Gurgaon is a luxury residential development offering 2 and 3 BHK apartments in Sector 113. The multi-story towers feature earthquake-resistant construction, advanced security, and a modern lobby. The project is a pre-launch development in Gurgaon.Business Wire BlogMPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment CommitteeMPM Capital added Detlev Biniszkiewicz, Ph.D., to its investment team as Managing Director and Investment Committee member. He joined in 2018 and has launched portfolio companies including NextPoint Therapeutics. He currently serves on iTeos Therapeutics' board.